Payment overview · 2025
General Payments
$109.10
6 reported records · 5 companies
Healthcare provider profile · identity verified
John Fell, DO
Allopathic & Osteopathic Physicians|Family Medicine · MUSKOGEE, OK · NPI 1629091640
Verified facts
What the public records show
CMS Open Payments records show John Fell, DO received $109.10 in general payments during 2025 across 6 reported records.
Astellas Pharma US Inc accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.97 | 41.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.39 | 16.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $15.81 | 14.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.71 | 14.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.22 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.10 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 221 | 38 |
| Gabapentin | Gabapentin | 184 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 49 |
| Methylprednisolone | Methylprednisolone | 141 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 118 | 50 |
| Lisinopril | Lisinopril | 112 | 36 |
| Azithromycin | Azithromycin | 107 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 29 |
| Clonazepam | Clonazepam | 96 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 87 | suppressed |
| Diazepam | Diazepam | 85 | 22 |
| Losartan Potassium | Losartan Potassium | 79 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 17 |
| Mounjaro | Tirzepatide | 74 | 12 |
| Trazodone Hcl | Trazodone Hcl | 72 | 29 |
| Montelukast Sodium | Montelukast Sodium | 69 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 16 |
| Meloxicam | Meloxicam | 65 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 24 |
| Baclofen | Baclofen | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Omeprazole | Omeprazole | 62 | 30 |
| Potassium Chloride | Potassium Chloride | 62 | 17 |
| Pregabalin | Pregabalin | 60 | 13 |
| Furosemide | Furosemide | 58 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 28 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Ibuprofen | Ibuprofen | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | 20 |
| Carvedilol | Carvedilol | 45 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 13 |
| Fluconazole | Fluconazole | 44 | 15 |
| Celecoxib | Celecoxib | 42 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Cephalexin | Cephalexin | 35 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 11 |
| Mirtazapine | Mirtazapine | 32 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 18 |
| Atenolol | Atenolol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | 11 |
| Eliquis | Apixaban | 29 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Simvastatin | Simvastatin | 27 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 11 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dipyridamole | Dipyridamole | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.10 · 6 records | Astellas Pharma US Inc | GLYCATE, JARDIANCE, RELTONE 200 MG, RELTONE 400 MG, VRAYLAR, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error